JP2019510079A - 血管収縮を特徴とする疾患を治療する方法 - Google Patents

血管収縮を特徴とする疾患を治療する方法 Download PDF

Info

Publication number
JP2019510079A
JP2019510079A JP2018563946A JP2018563946A JP2019510079A JP 2019510079 A JP2019510079 A JP 2019510079A JP 2018563946 A JP2018563946 A JP 2018563946A JP 2018563946 A JP2018563946 A JP 2018563946A JP 2019510079 A JP2019510079 A JP 2019510079A
Authority
JP
Japan
Prior art keywords
benzo
imidazol
carboxamide
piperidine
tetrahydrofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510079A5 (enExample
Inventor
ペール−ユーアン・ヤコブソン
Original Assignee
ジェシンタ・ファーマ・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェシンタ・ファーマ・アーベー filed Critical ジェシンタ・ファーマ・アーベー
Publication of JP2019510079A publication Critical patent/JP2019510079A/ja
Publication of JP2019510079A5 publication Critical patent/JP2019510079A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018563946A 2016-02-25 2017-02-24 血管収縮を特徴とする疾患を治療する方法 Pending JP2019510079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603311.0A GB201603311D0 (en) 2016-02-25 2016-02-25 New uses and methods
GB1603311.0 2016-02-25
PCT/GB2017/050498 WO2017144909A1 (en) 2016-02-25 2017-02-24 Methods of treating diseases characterised by vasoconstriction

Publications (2)

Publication Number Publication Date
JP2019510079A true JP2019510079A (ja) 2019-04-11
JP2019510079A5 JP2019510079A5 (enExample) 2020-04-02

Family

ID=55806947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563946A Pending JP2019510079A (ja) 2016-02-25 2017-02-24 血管収縮を特徴とする疾患を治療する方法

Country Status (9)

Country Link
US (2) US20190038603A1 (enExample)
EP (1) EP3419620A1 (enExample)
JP (1) JP2019510079A (enExample)
CN (1) CN109069487A (enExample)
AU (1) AU2017222406B2 (enExample)
CA (1) CA3014728A1 (enExample)
GB (1) GB201603311D0 (enExample)
RU (1) RU2018133818A (enExample)
WO (1) WO2017144909A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010015A1 (ja) * 2022-07-06 2024-01-11 あすか製薬株式会社 ピリミジン誘導体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079578A1 (en) 2017-10-19 2019-04-25 Amgen Inc. BENZIMIDAZOLE DERIVATIVES AND USES THEREOF
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
KR20210059663A (ko) * 2019-11-15 2021-05-25 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
GB202212749D0 (en) 2022-09-01 2022-10-19 Gesynta Pharma Ab New uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023812A1 (en) * 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
JP2012519205A (ja) * 2009-03-05 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗炎症剤としての３ｈ−イミダゾ［４，５−ｃ］ピリジン−６−カルボキサミド
WO2012117062A1 (en) * 2011-03-02 2012-09-07 Novasaid Ab Piperidinyl benzoimidazole derivatives as mpges-1 inihibitors
JP2013534236A (ja) * 2010-08-20 2013-09-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
WO2015158204A1 (zh) * 2014-04-14 2015-10-22 上海恒瑞医药有限公司 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298343A1 (en) * 2007-10-05 2010-11-25 John Howard Hutchinson 5-lipoxygenase-activating protein (flap) inhibitors
CA2844794C (en) * 2011-08-18 2018-02-20 Nippon Shinyaku Co., Ltd. Heterocyclic derivatives with mpges-1 inhibitory activity
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519205A (ja) * 2009-03-05 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗炎症剤としての３ｈ−イミダゾ［４，５−ｃ］ピリジン−６−カルボキサミド
WO2011023812A1 (en) * 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
JP2013534236A (ja) * 2010-08-20 2013-09-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
WO2012117062A1 (en) * 2011-03-02 2012-09-07 Novasaid Ab Piperidinyl benzoimidazole derivatives as mpges-1 inihibitors
WO2015158204A1 (zh) * 2014-04-14 2015-10-22 上海恒瑞医药有限公司 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM., (2013), 21, [11], P.2868-2878, JPN6021007005, ISSN: 0004784571 *
HISTORY OF CHANGE FOR STUDY:NCT02361034, [ONLINE], 2015-DEC-14, CLINI CALTRIALS.GOV ARCHIVE, NCT ID:, JPN6021041628, ISSN: 0004784575 *
J. CLIN. INVEST., (2006), 116, [5], P.1391-1399, JPN6021007008, ISSN: 0004784572 *
日内会誌, (2007), 96, [10], P.2165-2170, JPN6021041633, ISSN: 0004784573 *
混合性結合組織病, [ONLINE], 品川シーサイド皮膚・形成外科クリニック, (2010.06), [2021.10.14検索], イ, JPN6021041631, ISSN: 0004784574 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010015A1 (ja) * 2022-07-06 2024-01-11 あすか製薬株式会社 ピリミジン誘導体

Also Published As

Publication number Publication date
RU2018133818A (ru) 2020-03-25
GB201603311D0 (en) 2016-04-13
RU2018133818A3 (enExample) 2020-05-27
US20220218670A1 (en) 2022-07-14
CN109069487A (zh) 2018-12-21
AU2017222406A1 (en) 2018-08-30
WO2017144909A1 (en) 2017-08-31
CA3014728A1 (en) 2017-08-31
US20190038603A1 (en) 2019-02-07
AU2017222406B2 (en) 2022-06-02
EP3419620A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
US20220218670A1 (en) Methods of treating diseases characterised by vasoconstriction
US8207195B2 (en) Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
JP2024522736A (ja) がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用
US20090325960A1 (en) Method for treating inflammatory diseases using rho kinase inhibitor compounds
US20090325905A1 (en) Method for treating diseases associated with alterations in cellular integrity using rho kinase inhibitor compounds
US20090227602A1 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
TW449473B (en) Compositions for inhibition of the pathophysiologic actions in mammals of tumor necrosis factor-alpha
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
US20140051716A1 (en) Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
US7183285B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
EP4494701A2 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
SG171783A1 (en) Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
EP2636414A1 (en) Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
Peters et al. Histamine: metabolism, physiology, and pathophysiology with applications in veterinary medicine
US20070015779A1 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
KR20020073176A (ko) 불안증 개선 방법
TW200303214A (en) Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
US20080255217A1 (en) Preventive or therapeutic agent for cardiac dysfunction or myocardial injury caused by ischemia or ischemia reperfusion
EP2891490B1 (en) Beta-3 adrenoceptor agonists for the treatment of pulmonary hypertension due to left heart disease
US7163945B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
JP5788907B2 (ja) 疾患の治療に使用される化合物
CN1084620C (zh) 用于预防和治疗凝血噁烷a2介导的疾病的药物
Sluter et al. Novel, brain-permeable, cross-species benzothiazole inhibitors of microsomal prostaglandin E synthase-1 (MPGES-1) dampen neuroinflammation in vitro and in vivo
TWI441634B (zh) 4-（1-羥基-1-甲基乙基）-2-丙基-1-〔4-〔2-（四唑-5-基）苯基〕苯基〕甲基咪唑-5-羧酸、其藥理容許鹽或其藥理容許酯之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220530